Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 2/2000

01-03-2000

Antioxidants inhibit TNFα-induced motility and invasion of human osteosarcoma cells: Possible involvement of NFκB activation

Authors: Katsumi Harimaya, Kazuhiro Tanaka, Yoshihiro Matsumoto, Hideshi Sato, Shuichi Matsuda, Yukihide Iwamoto

Published in: Clinical & Experimental Metastasis | Issue 2/2000

Login to get access
Metadata
Title
Antioxidants inhibit TNFα-induced motility and invasion of human osteosarcoma cells: Possible involvement of NFκB activation
Authors
Katsumi Harimaya
Kazuhiro Tanaka
Yoshihiro Matsumoto
Hideshi Sato
Shuichi Matsuda
Yukihide Iwamoto
Publication date
01-03-2000
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 2/2000
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/A:1006791723233

Other articles of this Issue 2/2000

Clinical & Experimental Metastasis 2/2000 Go to the issue

OriginalPaper

Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines

OriginalPaper

Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells

OriginalPaper

Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells

OriginalPaper

Heat shock-mediated transient increase in intracellular 3′, 5′-cyclic AMP results in tumor specific suppression of membrane type 1-matrix metalloproteinase production and progelatinase A activation

OriginalPaper

The microscopic anatomy of experimental rat CC531 colon tumour metastases: Consequences for immunotherapy?

Legacy

Tissue inhibitors of metalloproteases: Regulation and biological activities
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits